Edwards Lifesciences Co. (NYSE:EW – Get Free Report) VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,262,521.36. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Edwards Lifesciences Stock Performance
EW traded down $0.73 during trading on Tuesday, hitting $68.90. 4,021,755 shares of the company traded hands, compared to its average volume of 4,580,660. The firm has a market cap of $41.52 billion, a P/E ratio of 29.72, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. The stock’s fifty day moving average is $67.31 and its 200 day moving average is $79.79. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter last year, the business earned $0.66 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on Edwards Lifesciences
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its holdings in Edwards Lifesciences by 57.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after acquiring an additional 2,390,137 shares in the last quarter. CCLA Investment Management lifted its position in Edwards Lifesciences by 100,739.7% during the first quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock valued at $134,092,000 after buying an additional 1,405,319 shares during the period. Swedbank AB purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth about $124,511,000. Sei Investments Co. raised its position in shares of Edwards Lifesciences by 162.7% in the 1st quarter. Sei Investments Co. now owns 1,465,719 shares of the medical research company’s stock worth $140,064,000 after purchasing an additional 907,688 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after purchasing an additional 809,605 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- Business Services Stocks Investing
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- The 3 Best Blue-Chip Stocks to Buy Now
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Using the MarketBeat Dividend Yield Calculator
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.